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Abstract
Issue addressed: Complete Health Improvement Program (CHIP) is a lifestyle modiﬁcation program that promotes healthy diet,
physical activity and stress management techniques. Among US CHIP participants, differences in gender responsiveness to
improvements in chronic disease risk factors were demonstrated. This study examined gender differences in outcomes to the CHIP
intervention in Australasia.
Methods: Changes in body weight, blood pressure (BP), blood lipid proﬁle and fasting plasma glucose (FPG) were assessed in 925
participants (34.3% men, mean age = 56.0  12.5 years; 65.7% women, mean age = 54.4  13.5 years) 30 days after program
commencement.
Results: Signiﬁcant reductions (P < 0.001) in all biometrics measured were found for men and women but were greater among
men for total (TC) and low-density lipoprotein cholesterol (LDL), triglycerides (TG), FPG, body mass index (BMI) and TC/high-density
lipoprotein cholesterol (HDL) ratio. Participants with highest baseline classiﬁcations of BMI, systolic BP, blood lipids and FPG
showed greatest reductions in 30 days.
Conclusions: CHIP more effectively reduced chronic disease risk factors among men than women. All participants, but particularly
men, entering the program with the greatest risk achieved the largest reductions. Possible physiological or behavioural factors
include food preferences, making commitments and differential support modes.
So what? Developers of lifestyle intervention programs should consider gender differences in physiological and behavioural
factors when planning interventions. In particular, developers should manage expectations of people entering lifestyle
interventions to increase awareness that men tend to respond better than women. In addition, this is a call for further research to
identify the underlying mechanisms responsible for the disproportionate responsiveness of males.
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Introduction
Chronic diseases are the leading causes of death and disability in
Australasia, as they are worldwide.1–3 Deaths from chronic diseases
are projected to increase by 15% by 2020.3 Chronic diseases place a
large burden on families and communities through increased
morbidity, with a subsequent major ﬁscal burden.1,2
Lifestyle modiﬁcation programs have been shown to be effective
in the treatment of chronic disease.4 The Complete Health
Improvement Program (CHIP), a community-based lifestyle
Journal compilation  Australian Health Promotion Association 2014

modiﬁcation program, developed in the US in 1986, has
demonstrated signiﬁcant reductions in selected chronic disease risk
factors among large cohorts from several countries, including
Australia and New Zealand.5–8
Gender differences in the prevalence of various chronic diseases
(e.g. cardiovascular disease and obesity) and in lifestyle behaviours
(e.g. dietary intake and physical activity associated with these
diseases) are well recognised.9–13 It is therefore important to
differentiate the gender responsiveness to lifestyle interventions
CSIRO Publishing
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and ﬁnd effective ways to address them. While CHIP programs in
Australasia have shown signiﬁcant reductions in several chronic
disease risk factors, the differential responsiveness of men and
women to the CHIP intervention has not been performed.5,6 The
present study examined the short-term responsiveness of men and
women to the CHIP intervention in Australia and New Zealand and
suggests possible hormonal, behavioural (e.g. food preferences),
physiological (e.g. adiposity and lean tissue mass), social (e.g. group
support) and/or psychological (e.g. commitment) factors that
should be considered by those responsible for the planning and
delivery of lifestyle interventions.

Methods
The CHIP intervention was delivered to 925 participants, who had
self-selected to participate in the program between May 2006 and
September 2012. There were no inclusion/exclusion criteria other
than the participant being able to pay the $300 program cost.
A total of 44 CHIP programs (mean group size 21, range 5–100) were
conducted at 26 locations throughout Australasia (138 participants
in 9 locations in Australia; 787 in 17 locations in New Zealand) over
this period. The Avondale College of Higher Education Ethics
Committee approved the study.
The Australasian CHIP interventions were advertised in the local
media (newspapers, radio) of the communities in which the
programs were being offered and in some instances local medical
practitioners recommended their patients to the program. The
intervention involved 16 x two-hour group sessions, delivered
four days a week, over 30 days. Each session involved viewing a
one-hour pre-recorded lecture, a cooking demonstration and group
discussion. Furthermore, where local health experts could be
appropriately sourced, shopping tours and guided exercise sessions
were also added to the sessions. Participants were educated on the
aetiology of chronic disease and the beneﬁts of positive lifestyle
choices, with particular attention given to encouraging and
supporting the consumption of a low-fat (<15% of calories from fat),
plant-based ad libitum diet. In addition, the program advocated
that participants engage daily in 30 min of moderate physical
activity (walking) and practise stress management techniques
(life balance, sleep, rest). Behaviour-change programs that include
these components have been shown to be effective at reducing
chronic disease by Ornish et al.4 In addition, sessions on overcoming
barriers to change, developing emotional intelligence and providing
participants with strategies (self-monitoring, goal setting and
problem solving; including addressing unsupportive social and
physical inﬂuences) for behaviour-change maintenance were also
included. For a discussion on the development and detailed
description of the CHIP program, the reader is referred to the review
article by Morton et al.14
The CHIP programs were conducted by volunteer facilitators, who
had an interest in positively inﬂuencing the health of their local
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community. All volunteers were required to undergo two days of
training to learn about the CHIP intervention and develop group
facilitation skills. There were no educational requirements or
selection criteria for the volunteer facilitators. The educational
component of the CHIP program intervention was presented
through the pre-recorded videos. The role of the volunteer
facilitator was to organise the meeting and to facilitate discussions
in the 16 group sessions. While the use of the supplied resources
meant that program delivery was consistent in each location, the
program may have varied with the addition of activities (e.g.
shopping tours and exercise sessions) depending on the volunteers
running these additional segments.
The participant was deemed to have completed the initial 30 days
of the program if they attended 13 of the 16 sessions (more than 80%
of the program) and underwent both pre- and post-assessments.
Before participating in the CHIP intervention (baseline) and again at
its conclusion (post-intervention), the participants’ height, weight,
SBP and DBP were taken and fasting (12-h) blood samples were
collected by registered health professionals. The same scales and
sphygmomanometer were used for taking measurements at
baseline and again at 30 days. The blood samples were collected by
trained phlebotomists and analysed by local pathology laboratories
for TC, LDL, HDL, TG and FPG levels.

Statistical analyses
The data were analysed using IBM Statistics (version 19) and
expressed as mean  s.d. Pearson’s chi-square was used to
determine the extent of differences between men and women for
demographic variables. A one-way multivariate analysis of variance
(MANOVA) was conducted to test the hypothesis that there would
be one or more mean differences between men and women for the
biometric measures. The extent of the changes (from baseline to
post-intervention) in the biometric measures was then assessed for
males and females separately, using paired t-tests. To examine
whether these gender differences were statistically signiﬁcant, a
new variable (change from pre- to post-) was created and
independent t-tests were performed. The McNemar’s chi-square
test was used to determine the extent of changes in the distribution
of participants by gender, across the various risk factor categories.
Participants’ weight were characterised in risk categories using
standard BMI cut-points for ‘normal’, ‘overweight’ and ‘obese’;15 BP
was classiﬁed using the 5th Joint National Committee for
Hypertension guidelines;16 and FPG was characterised according to
conventional ‘normal’, ‘impaired’ and ‘diabetic’ levels.17 The US
National Cholesterol Education Program Adult Treatment Panel III
(ATP III) classiﬁcation system16 was used to categorise the
participants for all risk factors, except total cholesterol, for which the
Framingham risk classiﬁcation18 was used as it includes ﬁve
cholesterol categories compared with only three in the ATP III
classiﬁcation system. Metabolic syndrome at baseline and after
intervention was classiﬁed according to the ‘harmonised
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Multivariate analysis of the biometric changes showed that the
covariance between men and women were assumed to be equal
(Box’s M of 588.91, P < 0.001). A statistically signiﬁcant MANOVA

N

As shown in Table 1, at program entry both men and women were
representative of an at-risk population with a mean BMI in the
‘obese’ category and elevated BP and LDL. On average, the women
had elevated TC and the men had ‘prediabetic’ FPG levels at
program entry. There were also some baseline differences in health
history, with more men than women commencing the intervention
with diagnosed conditions, such as, coronary bypass (2.8% vs 0.9%,
X2(1) = 4.29, P = 0.038) and stroke (2.4% vs 0.7%, X2(1) = 4.21,
P = 0.040). Men had higher baseline weight, SBP (t(868) = 3.13,
P < 0.002) and TC:HDL ratio, while the women had higher baseline
TC (t(858) = –5.56, P < 0.001), LDL (t(853) = –2.91, P = 0.004) and HDL
(t(858) = –10.52, P < 0.001) (Table 1). However, when the data was
split by risk category, women had higher baseline TC but only in the
range 4.14–5.17 mmol/L, LDL in the range 2.59–3.35 mmol/L and
HDL in the intermediate range (see Table 2).

30-days
Mean s.d.

Of the 925 participants who enrolled in the program, 891 (96%)
completed the initial 30 days of the intervention. Of these 891
participants, 34.3% (n = 301) were men and 65.7% (n = 590) were
women. There were no signiﬁcant difference in age between men
and women (56.0  12.5 years vs 54.4  13.5 years, t(890) = 1.76,
P = 0.079) and in the proportion reporting smoking ((4.4% vs 5.1%,
(X2(3) = 2.23, P = 0.527). More men reported being married than
women (84% vs 73%, (X2(3) = 18.36, P < 0.001). There were no
differences in the proportion of men and women who attended
the program each year between 2006 and 2012 (X2(6) = 5.30,
P = 0.506), in program location (X2(26) = 19.97, P = 0.793), or across
age groups (<30 years, 30–49 years, 50–69 years, 70+ years;
X2(3) = 5.74, P = 0.125).

Baseline
Mean s.d.

Results

Risk factor

deﬁnition’.19 Participants were deemed as having this syndrome if
they met three or more of the deﬁning criteria.19 Statistical tests were
two-sided with a signiﬁcance level of 5% (P < 0.05). Conﬁdence
intervals (95%) are also presented. In order to reduce the Type 1 error
that can occur when simultaneous tests are performed in a dataset,
a Bonferroni correction was applied separately to each biometric. As
there were a different number of risk category comparisons for each
biometric, the correction applied was 0.05/n, where n was the
number of categories within each biometric. Participants that did
not have baseline biometrics were removed. The remaining
participants were examined for missing data by sorting each
variable in ascending order. Data was considered to be missing
‘completely at random’ when there did not appear to be a
relationship between a missing data point and other values in the
dataset (e.g. for a missing lipid value, values for other lipids were
present, and there was no consistency in which variables had
missing values).

L. M. Kent et al.

%
change2
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Table 1. Mean changes in selected risk factors for men and women from baseline to 30 days, Australia and New Zealand, 2006–2012
**pre-post- mean change signiﬁcant at P < 0.001; 1t-test; ††difference in change between men and women signiﬁcant at P < 0.001 level of signiﬁcance; †difference in change between men and women signiﬁcant at
P < 0.05 level of signiﬁcance; zzbaseline difference signiﬁcant at P < 0.001 level of signiﬁcance, zbaseline difference signiﬁcant at P < 0.05 level of signiﬁcance; 2% change = ((mean at 30-days – mean at baseline)/
mean at baseline)*100
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Table 2. Changes in risk factor levels within 30 days by gender and initial risk factor classiﬁcation, Australia and New Zealand, 2006–2012
**pre-post- mean change signiﬁcant at P < 0.001; *Bonferroni correction applied: pre-post- mean change at P < 0.0167 level of signiﬁcance with three risk categories, P < 0.0125 with four risk categories, P < 0.01
with ﬁve risk categories; 1X2=McNemar Chi Squared statistic; 2t-test; ††difference in change between men and women signiﬁcant at P < 0.001 level of signiﬁcance; †Bonferroni correction applied: difference
in change between men and women at P < 0.0167 level of signiﬁcance with three risk categories, P < 0.0125 with four risk categories, P < 0.01 with ﬁve risk categories; zzbaseline difference signiﬁcant at P < 0.001
level of signiﬁcance, zBonferroni correction applied: baseline difference at P < 0.0167 level of signiﬁcance with three risk categories, P < 0.0125 with four risk categories, P < 0.01 with ﬁve risk categories;
3
% change = ((mean at 30-days – mean at baseline)/mean at baseline)*100
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–1.66** –2.48, –0.83

0.40
0.59
0.82
1.00

4.79 0.49
5.46 0.51
7.97 2.55
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4.83 0.48
5.87 0.35
9.22 2.26
175 59.9 229 78.4
90 30.8 49 16.8
27 9.2 14 4.8

X2 = 45.8**
Fasting Plasma Glucose (mmol/l)

<5.50
5.50–6.90
>6.90

0.32
0.17
0.65
0
1.10
1.92
3.03
13.0
194 65.8 235 79.7
54 18.3 32 10.8
46 15.6 28 9.5
1 0.3
0 0
<1.69
1.69–2.25
2.26–5.64
5.65

X2 undeﬁned
Triglycerides (mmol/l)

377 67.1 428 76.2
138 24.6 105 18.7
47 8.4 29 5.2
–1.0
–8.9
–26.7
–0.05
–0.14, 0.05
–0.52** –0.63, –0.41
–2.46** –3.67, –1.25
4.78 0.65
5.35 0.54
6.76 1.86

X2 = 40.1**

405 71.8 418 74.1
78 13.8 91 16.1
78 13.8 55 9.8
3 0.5
0 0
–9.1
–19.8
–25.7
–0.10** –0.15, –0.50
–0.38** –0.54, –0.21
–0.78** –1.06, –0.49
N/A
0.39
0.55
1.05
0
1.00
1.54
2.26
1.50

X2 undeﬁned

1.04
1.93
3.02
7.90

4.82
5.85
9.63

0.34
0.16
0.78
1.65

0.37
0.36
2.44

1.07
1.66
2.41
2.02
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effect was obtained, Pillai’s Trace = 0.29, F(11, 803) = 30.45, P < 0.001.
t-tests were then performed to examine mean differences between
men and women. The reductions were greater among the men
than women for BMI, TC, LDL, TG, FPG and TC:HDL ratio, but women
had greater reductions than the men for HDL (see Table 1).
Furthermore, more men than women signiﬁcantly decreased
their classiﬁcation of Metabolic Syndrome at 30 days (males:
43.2% to 32.5%, (X2(1) = 91.88, P < 0.001; females 38.3% to 34.8%,
(X2(1) = 259.10 P < 0.001).
Stratiﬁcation of risk factors showed substantive changes in the
distribution of men and women across the various categories, with
the largest reductions among participants with the highest risk
classiﬁcations at baseline (see Table 2). Furthermore, while statistical
analysis could not be performed for the proportional reduction of
men compared with women in each risk category examined
separately, it would appear that more men than women presenting
with the highest category for each of DBP (>100 mmHg), BMI
(>30 kg/m2), TC (>7.24 mmol/l) and LDL (4.91 mmol/l) reduced
their risk characterisation at 30 days (33% vs 21%, 20% vs 11%,
100% vs 81%, 100% vs 68%, respectively) (see Table 2). Furthermore,
for FPG levels indicative of diabetes (>6.99 mmol/l), more men than
women (48% vs 38%) appeared to have reduced their risk factor
categorisation in the 30 days. Conversely, in the highest risk category
for SBP (>160 mmHg) more women than men (60% vs 56%)
appeared to no longer be in this risk category (see Table 2). An
analysis of mean changes in the various biometric categories also
showed that men achieved greater improvements than the women.
For BMI, men experienced greater decreases than women in the
highest risk category for BMI; the lowest risk categories for TC and
LDL; and the lowest category for TG (see Table 2).

Discussion
Greater reductions in selected risk factors were achieved in 30 days
among men using the CHIP lifestyle intervention than women.
Furthermore, the majority of men in the highest risk classiﬁcations
for TC, LDL, TG and FPG showed improvement of more than 25% in
just 30 days; these improvements were greater than those of
women, though not statistically signiﬁcant, which could be due to
small sample sizes in these groups. It would appear this disparity
goes beyond higher baseline levels in men, as baseline levels of TC
and LDL were higher for women than for men. Of note, the gender
trends in baseline indices in this study are supported by national
Australian data.20 While the reasons for these differential gender
outcomes were not explored in this study, several factors, including
physiological and/or behavioural, could be speculated from the
literature.
In terms of physiological factors, differences in the distribution of
endogenous fat, may offer an explanation. Android fat around the
abdomen, is more common in men, while gynoid fat around the
buttocks, hips and thighs is more common in women.21 Android fat
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is more metabolically active and therefore easier to remove than
gynoid fat.21 Android fat also increases the risk of type 2 diabetes,
metabolic syndrome, cardiovascular disease (CVD), dyslipidaemias
and hypertension.22 Another factor may be the greater muscle mass
of men, which also contributes to their greater weight, compared
with women.22 Consequently, mechanically moving the greater
weight of men means men are more likely to lose more weight than
women.23 In addition, greater muscle mass is associated with higher
metabolic rate and therefore greater efﬁciency in expending
energy.24 Other physiological explanations may include the differing
hormonal proﬁle between men and women.25
Also related to physiological factors are differences in food
preferences and the amount of food eaten by men and women. Diets
high in whole-plant foods and low in red and processed meat may
provide beneﬁts for the prevention and treatment of not only
obesity but other chronic health problems, including type 2
diabetes and CVD.26 Plant foods are rich in ﬁbre and a range of
phytochemicals and antioxidants that are believed to confer these
aforementioned health beneﬁts.26 As population surveys show
that women tend to eat more fruit and vegetables than men, while
men’s diets tend to be higher in red and processed meats and
lower in ﬁbre,27 there is greater scope for men’s diets to include
more plant foods. Furthermore, the beneﬁt of the greater muscle
mass of men also means they have a greater requirement for
dietary energy than women, through greater intakes of food.28
Consequently, the higher intake of health-promoting plant foods
required to meet the energy demands of men, together with
increases in physical activity, as promoted by the CHIP intervention,
are therefore expected to more quickly ameliorate the adverse
effect of a previously poor lifestyle compared with the lower intakes
required by women. However, this hypothesis could not be
conﬁrmed as there is no information on uptake of the program,
especially relating to diet and physical activity.
From a behavioural standpoint, men may engage better with a
lifestyle program once committed, although getting them to
initially commit might be more challenging. Evidence from the
workplace would suggest that men seem to approach making the
commitment to change differently from women and are more
inclined to commit to a program if the beneﬁts outweigh the
costs.29 Results from weight-loss interventions have shown that if
men value the outcome, they are more likely to achieve goals they
set for themselves.30 They are also more likely to complete a program
that is prescriptive31 particularly if advised by a health professional.25
While women are inclined to commit to interventions for social
reasons (trust, interaction and obligations to signiﬁcant others), be
more eager to initially change behaviour and have higher
expectations of interventions than men, they are also more easily
disappointed and tend to drop out before reaching their goals.29,32
Therefore, while the literature suggests that men don’t engage with
behaviour-change programs (e.g. weight loss), there is anecdotal
evidence that once they have assessed and evaluated the evidence
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and made a commitment they can effectively engage in a
program30 and achieve better results in a shorter time than women
(pers. comm., Professor G Egger, Founder of Gut Busters, 13
September 2013). However, this could not be explored in this
study as information on commitment was not collected. The
difference in men’s and women’s engagement in the CHIP
intervention program needs to be explored in further research.
Having supportive relationships may be another behavioural factor
that may help explain the gender differences observed in this
study. Married men are less likely to engage in unhealthy, high-risk
behaviours.33 The contention that married men who attended the
CHIP intervention with their spouse beneﬁted from the ensuing
household changes made by the women is supported by the
literature.34 Although information on marital status was collected in
this study, information on attendance with a spouse was not. The
effect of marital status needs to be examined further, together with
other participant characteristics on the responsiveness to the CHIP
lifestyle intervention.
Even though men tend to access and use health services less
often than women,35 or be aware and concerned that they are
overweight,36 this study would indicate that the CHIP program can
have a positive effect on men’s health and men can do especially
well in 30 days compared with women. Results from the Pritikin
program also showed that men achieved greater reductions in
chronic disease risk factors from a lifestyle intervention than
women.37 Clearly several factors are at play, which could explain the
gender differences observed in this and other studies. These
include, but are not limited to, a range of physiological and
behavioural factors, ranging from fat and muscle distribution,
attitudes towards personal health and appearance, food
consumption patterns, self-efﬁcacy and commitment, and social
support. Broader research into the gender differences that
accompany lifestyle interventions may elucidate further factors.

Study limitations and strengths
In this study a greater proportion of men entered the program with
previously diagnosed health conditions, which may have
contributed to the higher baseline risk–factor levels of men
compared with women. Given these were small proportions (less
than 5%), it is unlikely that baseline-health history would have had a
major impact on the outcomes following the intervention.
Another limitation of this study is missing data. However, it is not
expected that missing data would have attenuated the outcomes
reported in this study, as the proportion of men and women who did
not return for follow-up assessment or did not have information
collected on all risk factors at follow-up was small (less than 5%)
but similar. Missing data was considered ‘missing completely at
random’.
A further limitation was the short follow-up time after which the
greater beneﬁts gained by the men may have been lost. A small
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New Zealand study found that 106 CHIP participants who returned
for follow-up assessment, on average four years after completion of
the intervention, were able to maintain improvements in most of
their biometrics.38 Furthermore, 71% of participants reported they
were still compliant to the CHIP principles after this time, but it
was not clear how this differed between men and women in this
study. As duration of the intervention effects and their costs-beneﬁts,
especially in comparison to non-intervention groups, is of key
interest to health promoters, the CHIP intervention should be
extended, for periods such as six months to ﬁve years.

assist in development of more effective lifestyle interventions for
both men and women. As lifestyle interventions, such as CHIP,
continue to be developed more research needs to be undertaken
to establish how best to meet the different needs of male and
female participants.

Lack of information to align risk factors with various behaviours was
a limitation of this study. Information on fat distribution, particularly
android fat and compliance measures in relation to dietary intake
and physical activity, would assist in explaining the reason for gender
differences. Furthermore, socioeconomic factors, such as social class
and ethnicity; who the participant attended the program with; and
readiness to change are important factors that may also have
contributed to the gender difference. Future studies should gather
valid measures of psychosocial factors and the various lifestyle
changes made by participants during the CHIP program to elucidate
their contribution to the results achieved.

3.

Notwithstanding the greater reductions among men, women did
achieve substantial risk reductions for most biometrics. More than
50% of men and women with higher baseline risk levels for SBP, TC,
LDL and TG reduced their risk characterisation after the 30-day
intervention. The changes in TC and LDL levels compare favourably
to those achieved by pharmaceutical interventions involving
statins,39 but without the risk, and are much greater than that
expected from dietary interventions aimed at lowering blood
lipids.40 In addition, almost half of men and more than one-third of
women characterised with diabetes reduced this characterisation.
These improvements translated to a 24.6% reduction in men and a
9.3% reduction in women who were characterised with Metabolic
Syndrome at baseline. Of note, risk factor characterisation of all
biometrics was reduced to at least the next lower level for both men
and women, but more so for men, with some participants reducing
two or three levels, particularly if they were in the higher risk
categories at baseline. As a result, the amount of change between
men and women in the highest baseline levels for TC, LDL and FPG
may not have reached signiﬁcance because of the small numbers
remaining in these risk categories at 30 days. However, without a
control group, generalising on effectiveness outside the study
sample is not possible.

Conclusions
The results of the present study indicate that men who participate in
the CHIP lifestyle intervention appear to achieve better outcomes
for reducing selected chronic disease factors in 30 days than women.
Deﬁning the gender-speciﬁc physiological and/or behavioural
factors that contribute to responsiveness to lifestyle change will
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